CTRI/2012/02/002463已完成未知
AN OPEN LABELLED EFFICACY AND TOLERABILITY STUDY OF NOVEL BETA-1- BLOCKER , NEBIVOLOL, ON HYPERTENSION WITH SPECIAL REFERENCE TO ENDOTHELIAL FUNCTION AND ARTERIAL STIFFNESS.
izams Institute of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •) Ambulatory, Male and Female Volunteers between 18-55 years of age with a Body Mass Index (BMI) of approximately 18-30 kg/m2 diagnosed with stageI hypertension
- •Essential Hypertension of greater than at least 1 month duration.
- •4) Stage 1 Hypertension with Systolic BP 140-159 or Diastolic BP 90-99 (JNC-7 Criteria) of greater than at least 1 month duration
排除标准
- •1)Secondary Hypertension.
- •2)Uncontrolled Hypertension.
- •3)History of Hypersensitivity to Beta Blockers or any component of the product.
- •4)Patients With Severe Bradycardia, Heart Block, Cardiogenic Shock, Decompensated Heart Failure, Sick Sinus Syndrome.
- •5)Females who are Pregnant or Lactating or planning to become Pregnant.
- •8)Subjects on Fluoxetine, Nicardipine, Cimetidine, Non- Dihydropyridine CCB?s and other CYP2D6 Inhibitors.
研究者
相似试验
招募中
2 期
Clinical Study of Synthetic Cannabidiol in Children and Adolescents with 22q11.2 Deletion SyndromePediatric 22q11.2 deletion syndromeNeurological - Other neurological disordersMental Health - Psychosis and personality disordersHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12619000673145Zynerba Pharmaceuticals Pty Ltd20
进行中（未招募）
1 期
A treatment study of ACH-0144471 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who Completed Clinical Study ACH471-100EUCTR2017-000665-79-GBAchillion Pharmaceuticals, Inc.12
进行中（未招募）
1 期
An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Homozygous Familial HypercholesterolemiaMedDRA version: 20.0 Level: PT Classification code 10020603 Term: Hypercholesterolaemia System Organ Class: 10027433 - Metabolism and nutrition disordersHomozygous Familial HypercholesterolemiaEUCTR2017-002297-39-FRSanofi-Aventis Recherche & Développement50
进行中（未招募）
1 期
An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Homozygous Familial HypercholesterolemiaMedDRA version: 20.0Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersHomozygous Familial HypercholesterolemiaEUCTR2017-002297-39-SISanofi-Aventis Recherche & Développement50
进行中（未招募）
1 期
An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Patients with Candidemia with Suspected Resistance to Standard of Care Antifungal TreatmentTreatment of non-neutropenic subjects with candidemia – inclusive of those subjects with suspected or confirmed antifungal-resistant candidemia with or without invasive candidiasisMedDRA version: 20.0Level: LLTClassification code 10060573Term: CandidemiaSystem Organ Class: 100000004862EUCTR2017-003571-56-ESAmplyx Pharmaceuticals, Inc.21